PTC wins bankruptcy auction for BLA-stage Fabry gene therapy ST-920 for $111M upfront

Filed August 13, 2026 · Period ending August 12, 2026 · ~1 min read

Key Changes

• high

  PTC selected as winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics bankruptcy for $111M upfront plus up to $100M in FDA approval milestones ($80M accelerated, $20M full approval).

  Item 8.01 verify on EDGAR →
• high

  Rolling BLA submission for accelerated approval expected to complete Q4 2026 based on 52-week Phase 1/2 STAAR study showing positive mean annualized eGFR slope, differentiated from other Fabry therapies that showed negative eGFR slope despite improved renal function.

  Item 8.01 verify on EDGAR →
• high

  Acquisition targets estimated 11,000 U.S. Fabry patients with one-time gene therapy designed to enable long-term enzyme production; transaction subject to bankruptcy court approval, antitrust review, and definitive documentation, expected to close late Q3 or early Q4 2026.

  Item 8.01 verify on EDGAR →